@tompowles1 Why do we now accept ~70-80% g3 AEs with IO + TKI's but the same relative toxicity with combining sunitinib or pazopanib to nivolumab was felt to be a "high incidence of high-grade toxicities limiting future development of either combination re
@VPrasadMDMPH @Plenary_Session @DrKarineTawagi Yes I like the CCTG idea, but interestingly early phase trials of sunitinib + ICI demonstrated high rates of toxicity. The specific TKI partner seems to be important.. https://t.co/iOaEyOK2P5
@SuyogCancer @neerajaiims @NEJM @DrChoueiri @motzermd @tompowles1 @urotoday @KCA_Journal @montypal @kidneycan @VivekSubbiah @PGrivasMDPhD @TiansterZhang @Huntsman_GU @umangtalking @KidneyCancer @DrVaishampayan Sunitinib and pazopanib were were studied in c
RT @jitcancer: Ahead of @sitcancer #kidneycancer webinar Jan 7: https://t.co/pF4NIIt1dI we spotlight our 2019 Best Clinical Paper - CM16: N…
RT @jitcancer: Ahead of @sitcancer #kidneycancer webinar Jan 7: https://t.co/pF4NIIt1dI we spotlight our 2019 Best Clinical Paper - CM16: N…
RT @jitcancer: Ahead of @sitcancer #kidneycancer webinar Jan 7: https://t.co/pF4NIIt1dI we spotlight our 2019 Best Clinical Paper - CM16: N…
RT @jitcancer: Ahead of @sitcancer #kidneycancer webinar Jan 7: https://t.co/pF4NIIt1dI we spotlight our 2019 Best Clinical Paper - CM16: N…
Ahead of @sitcancer #kidneycancer webinar Jan 7: https://t.co/pF4NIIt1dI we spotlight our 2019 Best Clinical Paper - CM16: Nivo + sunitinib or pazopanib https://t.co/bWdnIBy1fy. Not all PD1 + VEGF agents are the same - hope all join the discussion! #kcsm @
RT @jitcancer: @HHammersMD @bmsnews @sitcancer @brian_rini @ERPlimackMD @Uromigos @montypal @utswcancer Congratulations, Dr. Amin and fello…
@HHammersMD @bmsnews @sitcancer @brian_rini @ERPlimackMD @Uromigos @montypal @utswcancer Congratulations, Dr. Amin and fellow authors, for this recognition from #JITC editors! Keep up the great work! https://t.co/bWdnIBy1fy
@oncobalaji @NEJM Excess of toxicity with the combo of IO (Nivo) with different TKIs (Suni or Pazo): 70-82% G3-4 tox, 25-39% discont. https://t.co/u2BqReqxwN
RT @ERPlimackMD: 3/The #Checkmate016 trial is best known as the first ipi + nivo experience in #kidneycancer, but other cohorts looked at V…
3/The #Checkmate016 trial is best known as the first ipi + nivo experience in #kidneycancer, but other cohorts looked at VEGF + PD1 inhibition: nivolumab + sunitinib and nivolumab + pazopanib. https://t.co/rQ6vP18AgB https://t.co/qq7UWxjkfC
RT @sitcancer: #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal…
RT @CLebacle: Importance of careful selection of the anti-angiogenic drug and dose in the setting of combination regimens with immune check…
Importance of careful selection of the anti-angiogenic drug and dose in the setting of combination regimens with immune checkpoint inhibitors CheckMate 016 study #KidneyCancer #RCC #safety https://t.co/zXguBPxgL0
RT @sitcancer: #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal…
RT @sitcancer: #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal…
#JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study https://t.co/TyQb7PgDLX https://t.co/vOu05iLOAz
RT @sitcancer: #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal…
RT @sitcancer: #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal…
RT @sitcancer: #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal…
#JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study https://t.co/TyQb7PgDLX https://t.co/5SXOGlPmQz
RT @sitcancer: #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal…
RT @sitcancer: #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal…
RT @sitcancer: #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal…
RT @sitcancer: #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal…
#JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study https://t.co/TyQb7OZ2nn https://t.co/CBv6ImT04N
RT @JBrugarolas: Recent publication from Dr. Hammers encourages caution with combinations of nivolumab plus sunitinib or pazopanib: https:/…
Recent publication from Dr. Hammers encourages caution with combinations of nivolumab plus sunitinib or pazopanib (the CheckMate 016 study): https://t.co/XYJbbFPYEf
Recent publication from Dr. Hammers encourages caution with combinations of nivolumab plus sunitinib or pazopanib: https://t.co/LbvOAkysvX
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @HHammersMD: Yes, important to remind / spread the word. @montypal https://t.co/LFGEaBtJHI
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
Yes, important to remind / spread the word. @montypal
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
Great work indeed!
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
RT @montypal: Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the communi…
Thank you @HHammersMD @UTSWNews for publishing this study of sunitinib/pazopanib + nivo. Sends an impt message to the community - NOT safe to combine these drugs! I've seen it done in the community on occasion - BIG RISK! https://t.co/DD6k9LojSC https://t.
Safety and efficacy of #nivolumab in combination with #sunitinib or #pazopanib in advanced or metastatic renal cell carcinoma #CheckpointInhibitors #KinaseInhibitors #RenalCellCarcinoma #RCC #KidneyCancer @ERPlimackMD @FoxChaseCancer https://t.co/DHgEzriV
RT @sitcancer: New #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic re…
New #JITC Research: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study https://t.co/TyQb7PgDLX https://t.co/T5DQCyt3MO